Evidence map›Paper›PMID 38252675›Full record

ArticlePLoS pathogens2024

Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.

Michael W Grunst, Hwi Min Gil, Andres G Grandea, Brian J Snow, Raiees Andrabi, Rebecca Nedellec, Iszac Burton, Natasha M Clark, Sanath Kumar Janaka, Nida K Keles and 13 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Michael W GrunstDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Hwi Min GilWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Andres G GrandeaDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Brian J SnowDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Raiees AndrabiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Rebecca NedellecDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Iszac BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Natasha M ClarkDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Sanath Kumar JanakaDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Nida K KelesDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Ryan V MoriartyDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Andrea M WeilerWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Saverio CapuanoWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Christine M FennesseyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Thomas C FriedrichWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Shelby L O'ConnorDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
David H O'ConnorDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Aimee T BromanDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Lars HangartnerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
David T EvansDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0003-2498-6292
University of Wisconsin–Madison · USScripps Research Institute · USFrederick National Laboratory for Cancer Research · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
KIR and MHC Class I Immunogenetics in SIV InfectionR37AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2019 to 2026
$5.6M
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque modelR01AI167732 · NIAID · UNIVERSITY OF FLORIDA · PI David T Evans, Susana T Valente · 2021 to 2026
$4.3M
Assessing ADCC and Fc-mediated Protection against HIVR01AI148379 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T, FINZI, ANDRES · 2019 to 2023
$3.8M
Harnessing adaptive NK cell transfer to deplete viral reservoirsR01AI161816 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BARKER, EDWARD, EVANS, DAVID T · 2021 to 2025
$3.8M
Tethering lentiviral restriction to Fc-mediated antibody responsesR01AI155163 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2020 to 2024
$3.2M
KIR and MHC Class I Immunogenetics in SIV InfectionR01AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.7M
NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INIAID NIH HHS R01 AI095098NIAID NIH HHS R01 AI121135NIAID NIH HHS R01 AI148379NIAID NIH HHS R01 AI155163NIAID NIH HHS R01 AI161816NIAID NIH HHS R01 AI167732NIAID NIH HHS R37 AI095098NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI144462NIH HHS P51 OD011106
6 · The paper itself

Abstract

Fc-mediated antibody effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), can contribute to the containment HIV-1 replication but whether such activities are sufficient for protection is unclear. We previously identified an antibody to the variable 2 (V2) apex of the HIV-1 Env trimer (PGT145) that potently directs the lysis of SIV-infected cells by NK cells but poorly neutralizes SIV infectivity. To determine if ADCC is sufficient for protection, separate groups of six rhesus macaques were treated with PGT145 or a control antibody (DEN3) by intravenous infusion followed five days later by intrarectal challenge with SIVmac239. Despite high concentrations of PGT145 and potent ADCC activity in plasma on the day of challenge, all animals became infected and viral loads did not differ between the PGT145- and DEN3-treated animals. To determine if PGT145 can protect against a neutralization-sensitive virus, two additional groups of six macaques were treated with PGT145 and DEN3 and challenged with an SIVmac239 variant with a single amino acid change in Env (K180S) that increases PGT145 binding and renders the virus susceptible to neutralization by this antibody. Although there was no difference in virus acquisition, peak and chronic phase viral loads were significantly lower and time to peak viremia was significantly delayed in the PGT145-treated animals compared to the DEN3-treated control animals. Env changes were also selected in the PGT145-treated animals that confer resistance to both neutralization and ADCC. These results show that ADCC is not sufficient for protection by this V2-specific antibody. However, protection may be achieved by increasing the affinity of antibody binding to Env above the threshold required for neutralization.

Indexed as

Simian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsAntibodies, ViralAntibody-Dependent Cell CytotoxicityMacaca mulattaAntibodies, Viral

Identifiers

PMID38252675
PMCPMC10833561
OpenAlexW4391095533

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.